Sucampo Pharmaceuticals — Corporate Update (January 2017)
22 slides from Sucampo Pharmaceuticals's corporate update, Jan 9, 2017
Slide 1: Sucampo Pharmaceuticals, Inc. Corporate Update
January 2017 Sucampo Pharmaceuticals, Inc. Corporate Update
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains "forward - looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ
Slide 3: Non-GAAP Metrics
Non - GAAP Metrics 3 This presentation contains three financial metrics (Adjusted Net Income, EBITDA and Adjusted EBITDA) that are considered “non - GAAP” financial metrics under applicable Securities and Exchange Commission rules and regulations. These non - GAAP financial metrics should be conside
Slide 4: Investment Highlights
Investment Highlights 4 • Global biopharmaceutical company with proven track record of successful product development and focus on innovative R&D • Business model supports financial strength with significant EBITDA and cash flow to fuel continued transformation – Sustained revenue growth from AMITIZ
Slide 5: Proven and Experienced Management Team
Proven and Experienced Management Team 5 Peter Greenleaf Chief Executive Officer Peter Kiener, D.Phil Chief Scientific Officer Peter Lichtlen, M.D., Ph.D. Chief Medical Officer Matthias Alder Executive Vice President, Business Development & Licensing Steven Caffé, M.D. Senior Vice President, Global
Slide 6: Secure, Advance, Transform
Achieved Today 2017+ Revenue & Market Value Secure Advance Transform • Execute on pipeline opportunities − File LCM programs for regulatory approvals • BD strategy − Additional accretive transactions − Late stage development programs to strengthen, accelerate the pipeline − 4 transactions in 2016: −
Slide 7: Constipation Market Overview
Constipation Market Overview 7 Significant unmet need in efficacy, safety and patient satisfaction • U.S. constipation market is large and growing: ~$5B – Branded and generic Rx market: $4B / ~50M scripts/year (1) – OTC market: $800M / 23M units (30 - day supply) / year Opportunity to convert unsati
Slide 8: AMITIZA: Broadest Label in Constipation Market
AMITIZA: Broadest Label in Constipation Market 8 • Only product approved for all 3 constipation indications – Chronic Idiopathic Constipation (CIC): ~14% to 16% of adults globally – Irritable Bowel Syndrome - Constipation (IBS - C): ~15% of adults globally, 1/3 of which is IBS - C – Opioid Induced C
Slide 9: AMITIZA Prescription Growth is Sustained
9 U.S. TRx Scripts (1) 1104 155 853 1,092 1,118 1,122 1,185 1,231 1,288 1,345 1,457 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 9 mos 2016 (Thousands) AMITIZA Prescription Growth is Sustained First nine months of 2016 U.S. TRx YoY growth: 2% • Growth highlights strong and enduring position in
Slide 10: Competitive Overview
Competitive Overview 10 Drug Rx or OTC Company Target Indication Commentary CIC IBS - C OIC Rx Sucampo (Marketed by Takeda) x All adults x Adult women x All adults • Long history of usage • Well - tolerated product with an established safety profile • No limitation on duration of use Rx Ironwood (Ma
Slide 11: Blue-Chip Partnerships Provide Global Growth for AMITIZA
Blue - Chip Partnerships Provide Global Growth for AMITIZA 11 Takeda is global commercialization partner (except Japan, China) • Royalty arrangement in North America (18% – 26%) plus 9.5% from product sales • 50% split of annual AMITIZA net sales revenue for North America beginning January 2021 • Re
Slide 12: Recent Deals Have Unlocked Substantial AMITIZA Value
Recent Deals Have Unlocked Substantial AMITIZA Value 12 • Sucampo’s acquisition of R - Tech Ueno closed on 12/03/2015 • Secured a larger portion of the global economics of AMITIZA and greater control over the manufacturing and supply chain for the product • Settlement agreements with Par Pharmaceuti
Slide 13: New Pediatric Functional Constipation Indication
13 New Pediatric Functional Constipation (PFC) Indication • U.S. Prevalence: 18% of pediatric population (13.5M) • Unmet need: No FDA - approved therapies for PFC (black box warning for linaclotide; prucalopride failed in Phase 4); patients use OTC drugs off - label Phase 3 program in children 6 – 1
Slide 14: AMITIZA Growth Secured
AMITIZA Growth Secured x RTU acquisition increases AMITIZA revenue, captures add’l margin from vertically integrating mfg x Takeda extension • Net sales revenue split • Generic Agreements with Par & Dr. Reddy’s • Gross profit split x Underpenetrated markets with unsatisfied patients x Physician targ
Slide 15: Product Pipeline
Product Pipeline 15 Sucampo has the sole option to acquire an exclusive license to commercialize the CPP - 1X/sulindac combination product in North Am erica. Sucampo Program Option Program Target Indication(s) Development Stage (s)NDA / MAA Filing Approval Marketed Products AMITIZA CIC2 Chronic cons
Slide 16: CPP-1X/sulindac Combo: Exclusive Option for Phase 3 Asset in FAP
CPP - 1X/sulindac Combo: Exclusive Option for Phase 3 Asset in FAP 16 • Significant opportunity – Orphan indication in U.S. for familial adenomatous polyposis (FAP) • ~30K cases currently – No approved treatment options – Dire patient need • 100% risk of colon cancer • Progressive removal of colon/r
Slide 17: Pipeline Progress: Upcoming Milestones
Pipeline Progress: Upcoming Milestones 17 Product Event Expected Timing AMITIZA Initiation of Phase 3 pivotal alternate formulation in adults 2H16 AMITIZA File sNDA for PFC (6 – 17 years) 1H17 CPP - 1X/sulindac combination product Phase 3 futility analysis AMITIZA Top - line data from Phase 3 pivota
Slide 18: Strong Financial Performance
Strong Financial Performance 18 *A reconciliation of adjusted Net Income to GAAP Net Income and adjusted EBITDA to net income, the most directly comparable GAAP financial measure, is included in the Appendix. Summary of Results Q3 – 16 % Increase on Q3 – 15 Revenue $57.9M 49% Net Income GAAP $8.1M 1
Slide 19: 2016 non-GAAP Guidance
2016 non - GAAP Guidance Total Revenue: $220M – $225M Adjusted Net Income: $50M to $55M Adjusted Diluted EPS: $1.20 to $1.25 Adjusted EBITDA: $110M to $115M Strong Financial Performance, Continued 19 *One - time $10.0 million milestone in the fourth quarter of 2016 related to the achievement of sale
Slide 20: Appendix
Appendix
Slide 21: Consolidated Statements of Operations and Comprehensive Income
Consolidated Statements of Operations and Comprehensive Income (unaudited) (in thousands, except per share data) Three months ended September 30, 2016 2015 Adjusted Net Income: GAAP net income 8,092 7,205 Amortization Intangibles 6,672 - Intangible Impairment 7,286 - Legal Settlement (9,260) - Restr
Slide 22: Reconciliation for Non-GAAP Metrics
Reconciliation for Non - GAAP Metrics 22 Consolidated Statements of Operations and Comprehensive Income (unaudited) (in thousands, except per share data) For the year ended December 31 , 2015 2014 Adjusted Net Income: GAAP net income 33,371 13,128 Amortization Intangibles 3,732 - Amortization Invent
Sucampo Pharmaceuticals — Corporate Update (January 2017) on 6ix